A liraglutide case study reports that PurePep Easy Clean catch-and-release purification uses roughly 1,500 L of solvent per kilogram of peptide versus about 5,000 L for a 60 cm HPLC system, with throughput of 5 mol about 6 kg per run per day. The evidence supports PEC as an orthogonal polishing…
PurePep Easy Clean PEC can outperform a conventional preparative HPLC system on the two operational metrics reported in a liraglutide case study: solvent consumption drops from about 5,000 L to about 1,500 L per kilogram of purified peptide, and the process handles roughly 5 mol, or about 6 kg, of pre-purified liraglutide in a single run per day. Whether that makes PEC a replacement for HPLC is a separate question, and the public record does not answer it. The reported data position PEC as an orthogonal purification step that can absorb a large share of the purification load, not as a demonstrated single-step route from crude peptide to finished drug.
Manufacturing efficiency has become a competitive differentiator in peptide therapeutics for a structural reason: the molecules are complex, the purity specifications for injectable products are exacting, and the production cost per kilogram is dominated by downstream processing. Two manufacturers making the same molecule differ mainly in what happens after chain assembly. That is where the pressure to adopt orthogonal, higher-throughput purification methods enters the decision calculus, and it is why a vendor-developed technology with published case-study numbers earns attention despite its commercial origins.
The question is commercially significant because GLP-1 receptor agonists are the most heavily scaled class of peptide therapeutics in the industry. Fierce Pharma has projected annual sales for the class of close to $50 billion, a figure cited in the PEC literature; the year attached to that projection in the source text, 2014, is almost certainly a typographical error, since it predates the GLP-1 sales surge. Whatever the exact trajectory, the scale of demand creates direct pressure on manufacturers to find production methods that are faster and cheaper per kilogram while holding quality constant.
Liraglutide's clinical footprint makes it a reasonable test case for that pressure. Peptide Atlas's registry file for liraglutide records 239 registered clinical trials and 154 indexed PubMed papers. The phase breakdown shows 4 trials in Phase 2, 2 in Phase 4, and 1 in Phase 1, with 9 trials listed as recruiting and 1 as active. Recruiting studies extend well beyond the original diabetes indication. NCT07027969 is a Phase 4 trial of metabolic surgery for atrial fibrillation elimination in patients with atrial fibrillation, obesity, and obesity-related medical conditions. NCT06726577 is a Phase 1/Phase 2 trial of TP04HN106 in amyotrophic lateral sclerosis. NCT07301437 is a Phase 4 real-world study of liraglutide alone and in combination with orlistat for weight loss in adults with overweight or obesity. A molecule with that breadth of active investigation will need production-scale supply, so downstream purification capacity is a practical constraint, not an academic concern.
Traditional chromatographic purification separates peptide species by hydrophobicity on a packed column. A reversed-phase column is equilibrated with a polar mobile phase, loaded with the peptide mixture, and developed with a gradient of increasing organic solvent. More hydrophobic species, including the acylated variants common in GLP-1 drugs, elute later. The chemistry is effective and well characterized, which is why it dominates the industry. At production scale, the same chemistry becomes expensive in a specific way: the column must be equilibrated, loaded, washed, eluted, stripped, and re-equilibrated for every run, and each cycle moves many column volumes of solvent through the bed.
Column scale-up has a hard ceiling. Preparative columns cannot be made arbitrarily large: bed height is limited by the pressure the resin and hardware can withstand, and column diameter beyond a certain point creates flow distribution problems that erode resolution. The 60 cm diameter columns in the study sit near the practical limit of that path, which is why a manufacturer who needs more throughput must either run more columns in parallel, each with the same solvent load, or change the separation principle. Orthogonal technologies are attractive for exactly this reason: they reduce the load on the chromatographic bottleneck instead of adding another column beside it.
The comparison in the liraglutide study puts the solvent consumption of traditional HPLC at about 5,000 L per kilogram of purified peptide for systems built around 60 cm diameter columns. Solvent is not a minor line item. Organic mobile phases must be purchased, handled under safety controls, recovered or disposed of, and held within specification across the campaign. A step that cuts that volume by roughly two-thirds changes the operating cost and the environmental and safety footprint of a facility at the same time.
PEC is presented as a catch-and-release technology orthogonal to conventional chromatography. Orthogonal in this context means the separation is driven by a different physicochemical principle than reversed-phase hydrophobicity, so the two methods remove different impurities or partition the product differently. The vendor's public account does not disclose the chemistry of the catch step: whether the solid phase retains the target peptide, the impurities, or both is not stated in the available material. The operational description is that material is caught on a phase and released in purified form. The same account reports that the process was demonstrated from initial lab-scale testing through gram-scale production with consistent product quality as batch sizes increased.
One detail in the reported figures is easy to miss: the 5 mol per day throughput applies to pre-purified liraglutide. The PEC step in this case study is fed by material that has already passed through earlier purification stages. That means the reported performance describes PEC as a high-capacity orthogonal finishing step, not as the entire purification train. A manufacturer comparing PEC with HPLC should compare like with like: PEC plus its upstream steps against an HPLC-based process of equivalent total purity.
Berger et al. reported the liraglutide results in Chimica Oggi Chemistry Today , a journal covering applied chemistry. The vendor's account of the study, published February 24, 2025, translates the findings into three operational figures. Throughput: about 5 mol, or roughly 6 kg, of pre-purified liraglutide per run per day. Solvent use: about 1,500 L per kilogram of purified peptide with PEC versus about 5,000 L per kilogram for a traditional HPLC system with 60 cm diameter columns. Scale: consistent product quality from initial lab-scale testing through gram-scale production.
The operational logic of running an orthogonal step ahead of or beside HPLC is straightforward. In a single chromatographic method, impurities that co-elute with the product are the ones that defeat the separation. A second method with a different mechanism will distribute those co-eluting impurities differently, so the product collected from the second step has a different, usually cleaner, impurity profile. This is the standard rationale for orthogonal purification, and it is the most sensible reading of the PEC claims: not that chromatography is obsolete, but that a catch-and-release step can remove a class of impurities that reversed-phase HPLC handles poorly.
The throughput figure needs scrutiny before it enters a capacity model. The equivalence of 5 mol to roughly 6 kg is stated without the molecular-weight basis of the conversion, and the molar-to-mass relationship is not verified in the source. A mole is a count of molecules; converting it to a mass requires a defined molecular species and its mass. The public summary does not provide that basis. The same record that reports gram-scale production and a daily throughput figure also leaves unspecified how many parallel runs or systems would be needed to reach the daily output from the demonstrated batch size. None of this disproves the figure, but it is not yet a figure a plant engineer can build on.
The reported solvent comparison is the strongest quantitative claim in the record. At about 1,500 L per kilogram, PEC uses roughly a third of the solvent attributed to a 60 cm HPLC system at about 5,000 L per kilogram. If the comparison reflects matched product quality and comparable yield, the saving is material: solvent purchase, handling, and disposal are real costs in any purification campaign. But the comparison is narrow. It does not include total cost, yield, final purity, resin lifetime, labor, cleaning validation, or capital cost, none of which the public summary discloses. A solvent saving of 3,500 L per kilogram is not the same as a cost saving of that proportion. The source does not claim it is, but the surrounding context invites that reading.
The Peptide Atlas registry data put the manufacturing question in context. Liraglutide's 239 registered trials and 154 indexed PubMed papers reflect a molecule still under active clinical development. The distribution matters as much as the total. With 9 trials recruiting and 1 active, and with Phase 4 work running in areas as different as atrial fibrillation, obesity, and combination pharmacotherapy, the drug's supply chain must serve established diabetes volumes and new indications at the same time. Each indication that advances raises the required production capacity, and capacity in peptide manufacturing is set by the purification train.
The indexed literature shows the same pattern. Peptide Atlas records a systematic review and meta-analysis of diabetic retinopathy risk with GLP-1 receptor agonists PMID 42380920 , a study of how metabolic state shapes the brain and direct islet effects of liraglutide on insulin secretion PMID 42350670 , and a secondary analysis of the S-LiTE trial on exercise and liraglutide effects on vascular health during weight loss maintenance PMID 42342869 . Clinical attention remains high, and clinical attention converts into demand. In that setting, a claim that an orthogonal purification method handles a complex modified peptide at roughly one-third the solvent intensity is exactly the kind of claim a manufacturer should want to test. Peptide Atlas liraglutide reference page.
None of the clinical data speaks directly to PEC performance on semaglutide or tirzepatide, the other major GLP-1 molecules, and the case study itself is limited to liraglutide. Liraglutide is an acylated peptide with a fatty acid side chain that changes its hydrophobicity and its behavior on reversed-phase media. The structural features that make liraglutide a demanding purification challenge, the acylation and the peptide length, are shared in modified forms by other GLP-1 receptor agonists, but each analog has a distinct impurity profile. An orthogonal method proven on one peptide does not automatically transfer to another.
A manufacturer evaluating PEC should start by requesting the Berger et al. paper and asking two questions the public summary does not answer: what purity and yield were achieved for liraglutide, and what exactly is the catch-and-release chemistry. Purity and yield determine whether the solvent saving is real at matched product quality. The chemistry determines what drives the separation, which in turn determines which impurities the orthogonal step removes and which are left to the chromatographic steps.
The next step is a head-to-head on the manufacturer's own peptide and impurity profile. Orthogonality is a property of a pair of methods applied to a specific mixture, not a general property of a product. A catch-and-release step that separates liraglutide from its deletion and truncation impurities may behave differently on semaglutide, tirzepatide, or a peptide with a different acylation pattern. The reported consistency from lab scale to gram scale is encouraging, but a buyer should ask for multi-cycle data: how the phase performs over dozens or hundreds of runs, how it fouls, and how batch-to-batch reproducibility holds within the operating ranges of a GMP process.
A qualification campaign with the manufacturer's own material would settle the questions the vendor's summary leaves open. The campaign should define the purity target, spike the feed with known process-related impurities, and measure removal at several loadings. It should run enough consecutive cycles to establish the lifetime of the catch phase and the drift in product quality. It should compare the orthogonal step against the best available HPLC method on the same feed, using the same analytical methods, so that the solvent comparison is paired with a purity and yield comparison. None of this requires accepting the vendor's framing; it requires only a sample of the phase and a defined test plan.
The economic comparison should be built on total cost, not solvent volume alone. A complete model includes solvent purchase and disposal, the lifetime and cost of the catch phase, labor per batch, cleaning and regeneration cycles, capital cost of the equipment, and the cost of process validation. Validation matters specifically because adding an orthogonal purification step to a licensed process requires demonstrating that the step removes impurities, does not introduce new ones, and performs reproducibly. Those studies are not in the public summary, and they are not free.
For capacity planning, the stated throughput of about 5 mol, or roughly 6 kg, of pre-purified liraglutide per run per day is the right order of magnitude to test. The unresolved molar-to-mass conversion should be resolved with the study authors before the figure is used to size a plant. A manufacturer should also ask how the single-run-per-day figure scales: whether additional runs per day are feasible, whether the system can be paralleled, and where the practical limits sit. The record describes one run per day, not a demonstrated campaign at steady state.
The evidence base has structural limitations that a buyer should weigh. The figures originate with Gyros Protein Technologies, the vendor that sells PEC, and its account of the study carries the incentives of a product launch. The promotional framing attached to the original account is excluded from this analysis, but its existence is relevant context. Independent confirmation of the reported figures in the Berger et al. paper, or in a neutral third-party evaluation, would materially change the confidence a manufacturer can place in them.
The public record does not disclose the catch-and-release chemistry, the quantitative purity and yield for liraglutide, the capital and operating costs of a scaled PEC process, or performance on other GLP-1 receptor agonists. Each of these gaps is resolvable. The chemistry can be disclosed or investigated, purity and yield can be measured, capital costs can be quoted, and semaglutide and tirzepatide can be run through the same process. Until those data exist, the correct description of the evidence is that one vendor-linked case study on one peptide reports a large solvent saving and a credible throughput at a scale that remains partly unspecified.
The open questions for a manufacturer are specific:
For the reader's original question, the evidence-based answer is conditional. PEC can outperform a traditional HPLC system on the two metrics reported in the liraglutide case study: solvent use of about 1,500 L per kilogram versus about 5,000 L per kilogram for a 60 cm column system, and throughput of about 5 mol, roughly 6 kg, of pre-purified peptide per run per day. Whether it replaces HPLC depends on purity and yield data that have not been disclosed, on total cost, and on how the orthogonal step integrates with the rest of the purification train. The demonstrated fit is as a high-capacity orthogonal partner to chromatography, with the potential to cut solvent use by roughly two-thirds at the price of validating a new unit operation. That is a testable proposition. A manufacturer planning GLP-1 capacity should treat it as exactly that: a proposition to verify, not a settled replacement for the workhorse of peptide purification.
Peptides referenced: Semaglutide, Tirzepatide, Liraglutide, GLP-1.
Related reading: Balancing Chemistry and Timelines in Complex Peptide Synthesis, Hybrid Fragment Synthesis Expands Peptide Manufacturing Options, WorkBeads SEC Resins: Porosity, Selectivity and Operating Conditions, Therapeutic Peptides: Classes, Applications and Synthesis Challenges.